Avid Bioservices Inc (CDMO)

[biopharm]

John Silke

John completed a law degree in King's College London, before seeing the error of his ways and completing a second degree in Biochemistry at Churchill College, Cambridge (1992). He completed a PhD in Zurich (1997), Switzerland under Prof. Walter Schaffner, looking at the role of DNA methylation in the regulation of transcription. A Swiss fellowship allowed John to go to Australia to work on cell death mechanisms as a post-doc for Dr. David Vaux in the WEHI (1997-2005). After a five year stint running a lab in La Trobe University, he returned to the WEHI (2011) where his lab focuses on the programmed cell death pathways; apoptosis and necroptosis. He has collaborated with several pharmaceutical companies and is a strong advocate and proponent of using small drug like molecules to complement genetic analyses to investigate cell death pathways involved in regulating inflammation. In particular he is interested in the regulation of TNF signalling by TRAFs and Inhibitor of APoptosis proteins and their ability to regulate signalling cascades involving RIP Kinases.
http://www.tnf2015.org/content/john-silke

I think the new BODs must open up their list of experts to bring PS Targeting via Bavituximab and other PS Targeting ways into the spotlight and how Biomarkers discovered via their IP belongs to Peregrine, now Avid Bioservices which owns the IP assets